West Pharmaceutical Services (WST) Share-based Compensation (2011 - 2026)

West Pharmaceutical Services (WST) has reported Share-based Compensation for 16 consecutive years, with $10.9 million the latest figure, recorded in Q2 2026.

• Quarterly Share-based Compensation rose 47.3% year-over-year to $10.9 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $32.6 million (up 68.91% YoY) and the FY2025 annual result came in at $23.8 million, up 27.27% from the prior year.
• Share-based Compensation rose to $10.9 million in Q2 2026 per WST's latest filing, from $6.6 million in the prior quarter.
• Over the last five years, Share-based Compensation for WST reached as high as $18.8 million in Q1 2022 and fell as low as $1.4 million in Q4 2023.
• A 5-year average of $6.8 million and a median of $5.9 million in 2022 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2023 — Share-based Compensation plunged 67.44% — and 2024, when it soared 207.14%.
• Year by year, Share-based Compensation stood at $4.3 million in 2022, then tumbled by 67.44% to $1.4 million in 2023, then surged by 207.14% to $4.3 million in 2024, then surged by 55.81% to $6.7 million in 2025, then surged by 62.69% to $10.9 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $10.9 million, $6.6 million, and $6.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.